These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20209644)

  • 1. Predictors of embolization during protected renal artery angioplasty and stenting: Role of antiplatelet therapy.
    Kanjwal K; Cooper CJ; Virmani R; Haller S; Shapiro JI; Burket MW; Steffes M; Brewster P; Zhang H; Colyer WR
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):16-23. PubMed ID: 20209644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete versus partial distal embolic protection during renal artery stenting.
    Kanjwal K; Haller S; Steffes M; Virmani R; Shapiro JI; Burket MW; Cooper CJ; Colyer WR
    Catheter Cardiovasc Interv; 2009 May; 73(6):725-30. PubMed ID: 19198007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Embolic protection and platelet inhibition during renal artery stenting.
    Cooper CJ; Haller ST; Colyer W; Steffes M; Burket MW; Thomas WJ; Safian R; Reddy B; Brewster P; Ankenbrandt MA; Virmani R; Dippel E; Rocha-Singh K; Murphy TP; Kennedy DJ; Shapiro JI; D'Agostino RD; Pencina MJ; Khuder S
    Circulation; 2008 May; 117(21):2752-60. PubMed ID: 18490527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Appropriate patient and device selection crucial for clinical benefit following renal stenting.
    Zeller T
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):24-5. PubMed ID: 20578189
    [No Abstract]   [Full Text] [Related]  

  • 5. Determinants of renal function in patients with renal artery stenosis.
    Yu H; Zhang D; Haller S; Kanjwal K; Colyer W; Brewster P; Steffes M; Shapiro JI; Cooper CJ
    Vasc Med; 2011 Oct; 16(5):331-8. PubMed ID: 21908683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of outcome for renal artery stenting performed for salvage of renal function.
    Modrall JG; Timaran CH; Rosero EB; Chung J; Arko FA; Valentine RJ; Clagett GP; Trimmer C
    J Vasc Surg; 2011 Nov; 54(5):1414-1421.e1; discussion 1420-1. PubMed ID: 21803522
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal artery stenting in patients with chronic ischemic heart disease.
    Trani C; Tommasino A; Giammarinaro M; Burzotta F; Coroleu SF; Rufini V; Mazzari MA; Porto I; Niccoli G; Leone AM; Mongiardo R; Gabrielli FA; Schiavoni G; Biamino G; Crea F
    Catheter Cardiovasc Interv; 2010 Jul; 76(1):26-34. PubMed ID: 20578190
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting.
    Bagur R; Bertrand OF; Rodés-Cabau J; Larose E; Rinfret S; Nguyen CM; Noel B; Larochellière RD; Poirier P; Costerousse O; Roy L
    Catheter Cardiovasc Interv; 2009 Dec; 74(7):1010-6. PubMed ID: 19753635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction.
    Stone GW; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Carroll JD; Rutherford BD; Lansky AJ;
    N Engl J Med; 2002 Mar; 346(13):957-66. PubMed ID: 11919304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized, double-blind, placebo-controlled trial of abciximab for prevention of in-stent restenosis in diabetic patients after coronary stenting: results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial.
    Chen WH; Kaul U; Leung SK; Lau YK; Tan HC; Leung AW; Lee MK; Li SK; Ng W; Lee PY; Lam KF; Tse HF; Lau CP
    J Invasive Cardiol; 2005 Oct; 17(10):534-8. PubMed ID: 16204748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of thienopyridine administration prior to primary stenting in acute myocardial infarction.
    Rabbani LE; Iyengar S; Dangas GD; Grines CL; Cox DA; Garcia E; Tcheng JE; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Stant J; Fahy M; Lansky AJ; Mehran R; Stone GW
    J Interv Cardiol; 2009 Aug; 22(4):378-84. PubMed ID: 19496901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of abciximab on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction treated with primary stenting.
    Jeremias A; Vasu S; Gruberg L; Kastrati A; Stone GW; Brown DL
    Catheter Cardiovasc Interv; 2010 May; 75(6):895-902. PubMed ID: 20088008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial).
    Dangas G; Aymong ED; Mehran R; Tcheng JE; Grines CL; Cox DA; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Lansky AJ; Stone GW;
    Am J Cardiol; 2004 Oct; 94(8):983-8. PubMed ID: 15476608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients' data with long-term follow-up.
    Montalescot G; Antoniucci D; Kastrati A; Neumann FJ; Borentain M; Migliorini A; Boutron C; Collet JP; Vicaut E
    Eur Heart J; 2007 Feb; 28(4):443-9. PubMed ID: 17251257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome in elderly patients undergoing primary coronary intervention for acute myocardial infarction: results from the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Guagliumi G; Stone GW; Cox DA; Stuckey T; Tcheng JE; Turco M; Musumeci G; Griffin JJ; Lansky AJ; Mehran R; Grines CL; Garcia E
    Circulation; 2004 Sep; 110(12):1598-604. PubMed ID: 15353506
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of FiberNet® embolic protection system in patients undergoing angioplasty for atherosclerotic renal artery stenosis.
    Laird JR; Tehrani F; Soukas P; Joye JD; Ansel GM; Rocha-Singh K
    Catheter Cardiovasc Interv; 2012 Feb; 79(3):430-6. PubMed ID: 21805607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.
    Hamm CW; Heeschen C; Goldmann B; Vahanian A; Adgey J; Miguel CM; Rutsch W; Berger J; Kootstra J; Simoons ML
    N Engl J Med; 1999 May; 340(21):1623-9. PubMed ID: 10341274
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.